VanEck Pharmaceutical ETF
PPH
51 hedge funds and large institutions have $57.2M invested in VanEck Pharmaceutical ETF in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 6 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
6% less funds holding
Funds holding: 54 → 51 (-3)
9% less capital invested
Capital invested by funds: $62.9M → $57.2M (-$5.76M)
9.34% less ownership
Funds ownership: 27.43% → 18.09% (-9.3%)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
58% less call options, than puts
Call options by funds: $866K | Put options by funds: $2.07M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$6.94M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.34M |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
+$261K |
| 4 |
Morgan Stanley
New York
|
+$160K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$96.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$3M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.89M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.19M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$886K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$264K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RJA
51
Raymond James & Associates
St Petersburg,
Florida
| – | -$264K | -3,609 | Closed |
|
52
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$240K | -3,280 | Closed |
|
|
ASN
53
Advisory Services Network
Atlanta,
Georgia
| – | -$120K | -1,636 | Closed |
|
|
PSIWM
54
Paradigm Strategies in Wealth Management
Maple Grove,
Minnesota
| – | -$60K | -818 | Closed |
|
|
APA
55
American Portfolios Advisors
Holbrook,
New York
| – | -$2.41K | -33 | Closed |
|
PPH Hedge Fund Activity: Q3 2021 in Review
51 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2021, worth a combined $57.2M — down 9.2% from $62.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PPH and 4 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 16 added.
The largest buyer was Clough Capital Partners, opening a new position worth an estimated $6.94M. The largest seller was Bank of America, cutting an estimated $3M.
- 51 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2021, down from 54 in Q2 2021.
- Funds reported $57.2M of VanEck Pharmaceutical ETF stock for Q3 2021, down 9.2% quarter-over-quarter.
- 4 funds opened new VanEck Pharmaceutical ETF positions in Q3 2021 and 6 closed out, a net change of -2 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2021 was Clough Capital Partners, an estimated $6.94M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2021 was Bank of America, an estimated $3M sold.
Based on aggregated 13F filings for Q3 2021.